Journal of Molecular BiologyBiochemistryPeer-reviewed journal article
Uncompetitive Allosteric Inhibitor of Mitochondrial Creatine Kinase Prevents Binding and Release of Creatine by Stabilization of Loop Closure
Merve DemiriD, Chen-Ting Ma, Nikhil Puvvula, Laura KoeppingiD, Palak Gosalia, Sirkku PollariiD, Shaun Alba, Zoe Zong, Ya LiiD, Lynn Miya FujimotoiD, Andrey A. BobkoviD, Taro HitosugiiD, Jianhua ZhaoiD, Eduard A. SergienkoiD
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 33th percentile
Abstract
Mitochondrial creatine kinase (MtCK) is a key enzyme in energy buffering and homeostasis in cells. It catalyzes transfer of phosphoryl group from ATP to creatine. Overexpression of MtCK occurs in many cancer cells to meet elevated energy demands, which is associated with poor prognosis. This suggests that MtCK may be a promising target for cancer therapeutics. We sought to discover first-in-class selective inhibitors of MtCK with diverse mechanisms of action using high-throughput screening, biochemical characterization and cryo-EM studies. Through these studies, we identified diverse types of compounds that modulate activity of MtCK in vitro, including fast-equilibrium and time-dependent orthosteric and allosteric inhibitors. Select hits were subjected to in vitro enzymatic and binding assays to assess MtCK inhibition and binding. A subset of inhibitors was advanced into structural studies using cryo-EM resulting in the molecular structure of MtCK with and without bound substrates in complex with an allosteric uncompetitive inhibitor that we discovered. These studies identified compounds unique binding pocket on MtCK and established the molecular steps manifesting in the apparent uncompetitive mode of inhibition. We demonstrate that the compound stabilizes an active site loop in a closed conformation restricting access of the creatine substrate to and the release of phosphocreatine product from its binding pocket. These findings establish chemical tools suitable for validation of MtCK as a promising breast cancer target with high therapeutic potential and build a foundation for future structure-guided optimization of the hit compounds of MtCK we identified and de novo rational design of novel MtCK inhibitors. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=160 SRC="FIGDIR/small/696683v1_ufig1.gif" ALT="Figure 1"> View larger version (21K): org.highwire.dtl.DTLVardef@1fd9870org.highwire.dtl.DTLVardef@230e31org.highwire.dtl.DTLVardef@178d8fdorg.highwire.dtl.DTLVardef@edeca6_HPS_FORMAT_FIGEXP M_FIG C_FIG
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structural Basis for Substrate Binding, Catalysis and Inhibition of Breast Cancer Target Mitochondrial Creatine Kinase by Covalent Inhibitor via Cryo-EM
Merve Demir, Laura Koepping, … Eduard A. Sergienko·StructurePeer-reviewed·Jun 18, 2024
- Proposed allosteric inhibitors bind to the ATP site of CK2α
Paul Brear, Darby Ball, … Marko Hyvonen·Journal of Medicinal ChemistryPeer-reviewed·Oct 29, 2020
- Structural Analysis of Inhibitor Binding to CAMKK1 Identifies Features Necessary for Design of Specific Inhibitors
A. d. S. Santiago, R. M. Counago, … J. Elkins·bioRxiv·Mar 31, 2018
- Catalytic domain plasticity of MKK7 reveals structural mechanisms of allosteric activation and new targeting opportunities
M. Schroeder, L. Tan, … A. Chaikuad·bioRxiv·Jun 11, 2020
- Synthesis and evaluation of chemical linchpins for highly selective CK2α targeting
Francesco A. Greco, Andreas Krämer, … Stefan Knapp·European Journal of Medicinal ChemistryPeer-reviewed·Jul 14, 2024
- Crystal structure of activated MAPKAPK2 kinase reveals a C-lobe allosteric pocket for furan-2-carboxamide inhibitors
Edward Beaumont, Stéphanie Duclos, … john Barker·bioRxiv·Oct 7, 2026